Verwandte Artikel zu Effectiveness and Safety of Radium-223 Dichloride:...
Inhaltsangabe
Radium-223 dichloride (Ra-223) is an alpha particle-emitting radiopharmaceutical whose licensed indication in patients with castration-resistant prostate cancer with bone metastases (CRPCm) was modified in June 2018, due to the appearance of drug-drug interactions with common drugs in CRPCm such as abiraterone and prednisone/prednisolone. Thus, it was restricted to use in monotherapy or combination with luteinizing hormone-releasing hormone analogues, becoming third-line treatment in patients with CRPCm, for which evidence on its effectiveness and safety in this new context is lacking.
Die Inhaltsangabe kann sich auf eine andere Ausgabe dieses Titels beziehen.
Über die Autorin bzw. den Autor
Laureato in farmacia e specializzato in Radiofarmacia.
„Über diesen Titel“ kann sich auf eine andere Ausgabe dieses Titels beziehen.
Suchergebnisse für Effectiveness and Safety of Radium-223 Dichloride:...
Beispielbild für diese ISBN
Effectiveness and Safety of Radium-223 Dichloride
Verlag:
Our Knowledge Publishing Okt 2023, 2023
ISBN 10: 6206581640
ISBN 13: 9786206581642
Neu
Taschenbuch
Anbieter: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Deutschland
Verkäuferbewertung 5 von 5 Sternen
Taschenbuch. Zustand: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Radium-223 dichloride (Ra-223) is an alpha particle-emitting radiopharmaceutical whose licensed indication in patients with castration-resistant prostate cancer with bone metastases (CRPCm) was modified in June 2018, due to the appearance of drug-drug interactions with common drugs in CRPCm such as abiraterone and prednisone/prednisolone. Thus, it was restricted to use in monotherapy or combination with luteinizing hormone-releasing hormone analogues, becoming third-line treatment in patients with CRPCm, for which evidence on its effectiveness and safety in this new context is lacking. 60 pp. Englisch. Bestandsnummer des Verkäufers 9786206581642
Neu kaufen
EUR 45,90
EUR 23,00 Versand
Versand von Deutschland nach USA
Versand von Deutschland nach USA
Anzahl: 2 verfügbar
Foto des Verkäufers
Effectiveness and Safety of Radium-223 Dichloride : Modifications in its indication
Print-on-DemandAnbieter: AHA-BUCH GmbH, Einbeck, Deutschland
Verkäuferbewertung 5 von 5 Sternen
Taschenbuch. Zustand: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Radium-223 dichloride (Ra-223) is an alpha particle-emitting radiopharmaceutical whose licensed indication in patients with castration-resistant prostate cancer with bone metastases (CRPCm) was modified in June 2018, due to the appearance of drug-drug interactions with common drugs in CRPCm such as abiraterone and prednisone/prednisolone. Thus, it was restricted to use in monotherapy or combination with luteinizing hormone-releasing hormone analogues, becoming third-line treatment in patients with CRPCm, for which evidence on its effectiveness and safety in this new context is lacking. Bestandsnummer des Verkäufers 9786206581642
Neu kaufen
EUR 48,74
EUR 35,00 Versand
Versand von Deutschland nach USA
Versand von Deutschland nach USA
Anzahl: 1 verfügbar
Foto des Verkäufers
Effectiveness and Safety of Radium-223 Dichloride
Anbieter: moluna, Greven, Deutschland
Verkäuferbewertung 5 von 5 Sternen
Zustand: New. Bestandsnummer des Verkäufers 1188787031
Neu kaufen
EUR 37,04
EUR 48,99 Versand
Versand von Deutschland nach USA
Versand von Deutschland nach USA
Anzahl: Mehr als 20 verfügbar
Foto des Verkäufers
Effectiveness and Safety of Radium-223 Dichloride
Verlag:
Our Knowledge Publishing Okt 2023, 2023
ISBN 10: 6206581640
ISBN 13: 9786206581642
Neu
Taschenbuch
Anbieter: buchversandmimpf2000, Emtmannsberg, BAYE, Deutschland
Verkäuferbewertung 5 von 5 Sternen
Taschenbuch. Zustand: Neu. This item is printed on demand - Print on Demand Titel. Neuware -Radium-223 dichloride (Ra-223) is an alpha particle-emitting radiopharmaceutical whose licensed indication in patients with castration-resistant prostate cancer with bone metastases (CRPCm) was modified in June 2018, due to the appearance of drug-drug interactions with common drugs in CRPCm such as abiraterone and prednisone/prednisolone. Thus, it was restricted to use in monotherapy or combination with luteinizing hormone-releasing hormone analogues, becoming third-line treatment in patients with CRPCm, for which evidence on its effectiveness and safety in this new context is lacking.VDM Verlag, Dudweiler Landstraße 99, 66123 Saarbrücken 60 pp. Englisch. Bestandsnummer des Verkäufers 9786206581642
Neu kaufen
EUR 45,90
EUR 60,00 Versand
Versand von Deutschland nach USA
Versand von Deutschland nach USA
Anzahl: 1 verfügbar